Research Article

Prognostic Nutritional Index and Neutrophil/Lymphocyte Ratio Can Serve as Independent Predictors of the Prognosis of Hepatocellular Carcinoma Patients Receiving Targeted Therapy

Wei Chen, Mingjun Zhang, Chanjuan Chen, and Xiaonan Pang 💿

Department of Oncology, Second Affiliated Hospital of Anhui Medical University, Hefei 230601, Anhui, China

Correspondence should be addressed to Xiaonan Pang; pxnfighting@mail.nankai.edu.cn

Received 18 May 2022; Revised 13 June 2022; Accepted 1 July 2022; Published 11 August 2022

Academic Editor: Jinghua Pan

Copyright © 2022 Wei Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The prognostic nutritional index (PNI) is an immunonutritional indicator, and the neutrophil/lymphocyte ratio (NLR) reflects the inflammatory status. This research intends to determine the implications of NLR and PNI in evaluating the outcome of hepatocellular carcinoma (HCC) patients undergoing targeted therapy (TT). Methods. We retrospectively analyzed 83 patients' records with sorafenib treatment for advanced HCC in the Second Affiliated Hospital of Anhui Medical University. Patient records comprised general data and blood routines. The PNI and NLR values were calculated using the serum albumin levels (ALB), neutrophil (NEU) count, and lymphocyte (LY) count. The optimal thresholds of the PNI and NLR for predicting HCC patients' outcomes were calculated by X-tile. Patients were further assigned to low- and high-groups of PNI and NLR according to their thresholds. By using the Cox proportional hazards regression models, univariate and multivariate analyses were conducted to identify risk factors influencing the patient's prognosis. *Results*. The participants were assigned to the corresponding low-PNI $(\leq 42.9; n = 10)$ and high-PNI (> 42.9; n = 73) groups, as well as low-NLR $(\leq 2.4; n = 64)$ and high-NLR (> 2.4; n = 19) groups based on the critical values of PNI (42.9) and NLR (2.4) obtained through the X-tile calculation. A higher overall survival (OS) rate was observed in the high-PNI group and low-NLR group, than in the low-PNI group and high-NLR group, respectively. The disease control rate showed no evident difference between the groups. The PNI and NLR were of high reliability in predicting the OS of patients. Cox multivariate analysis identified the independence of the PNI and NLR as prognostic factors for patients receiving TT for advanced HCC. Conclusions. The pretreatment PNI and NLR levels have great prognostic implications for advanced HCC patients receiving TT. A higher PNI and a lower NLR suggest a higher postoperative survival rate.

1. Introduction

Primary liver cancer (LC) ranks 6th in incidence among the neoplastic diseases and 3rd in cancer mortality [1], inflicting nearly 906,000 new cases and causing 830,000 deaths in the year 2020 [2]. The main risk factors of LC vary from region to region, with aflatoxin exposure, chronic hepatitis B virus (HBV) infection, or both being the key decision factors in most at-risk districts (China, South Korea, and sub-Saharan Africa) [2]. In addition, excessive drinking is also one of the risk factors [3]. The primary LC has several subtypes, among which HCC (HCC) is the most prevalent, accounting for 78% of all LC cases [1]. Currently, surgery is still recognized as the most effective means to treat early and middle-stage

HCC. However, due to the characteristics of insidious onset, rapid development, and high degree of malignancy, more than 70% of the cases are diagnosed at advanced stages when surgery is not applicable, with a postoperative recurrence rate as high as 70% [4].

Transcatheter arterial chemoembolization (TACE) based interventional therapy [5] is mainly used for advanced HCC patients, but it is not so effective in improving patients' survival and life quality [6]. As clinical research advances, molecularly targeted agents such as sorafenib, lenvatinib, stivarga, bevacizumab, and ramucirumab have opened a new chapter in the systemic treatment of advanced HCC, which can prolong patient survival to a certain extent [7–11]. However, regarding the prediction of HCC patients' outcomes, the conventional prognostic indices such as tumour size, blood vessel invasion, and other surgical resection-related factors [12] are less convenient in clinical testing, with limited ability to predict patient outcomes after the targeted therapy (TT). Therefore, it is necessary to find novel indices with the prognostic utility to assist in predicting the clinical outcomes of HCC patients after TT. Existing research indicates that systemic inflammatory response and systemic nutritional status indicators are critical in the prognostic risk assessment of malignant tumors [13]. Besides, related studies have shown that inflammation directly affects tumor cell growth. Inflammation benefits tumour formation, progression, and metastasis, and chronic inflammation has an association with an elevated cancer risk [14, 15]. Immune status, including the nutritional status and inflammation state, is important for the survival of patients with cancer of various types, including HCC. With the deepening of people's understanding of tumor-related inflammation, biomarkers of systemic inflammation like Creactive protein (CRP) level, as well as the ratio of neutrophil/lymphocyte lymphocyte-to-monocyte (NLR), (LMR), and platelet-to-lymphocyte (PLR), have been welldocumented to be able to predict the prognosis of neoplastic diseases, including lung carcinoma [16], gastric carcinoma [17], and liver carcinoma [18]. But the prognosis of tumor patients depends not only on tumor pathology and immune factors but also on the host state, such as the patient's nutritional status [19]. Evidence has shown that the incidence of malnutrition in malignant tumor patients is as high as 40%-80%, with approximately 30% of cancer deaths resulting from malnutrition and its resulting complications, rather than the tumor itself [20]. The prognostic nutritional index (PNI) was developed by Smale et al. [21] and was initially used for preoperative nutritional status and postoperative complication assessment and is calculated from the serum albumin (ALB) level and the peripheral blood (PB) and lymphocyte (LY) count. As a nutritional-immune index, it has been confirmed to be a prognostic index for various malignancies, such as gastric, pancreatic, and esophageal carcinomas [22-24]. A meta-analysis examining the correlation of PNI with tumor survival from 14 papers found that low-PNI levels were linked to adverse overall survival (OS) in terms of tumor type, operation conditions, threshold, as well as sample size and area [25]. Another research compared the PNI before and after the operation and confirmed the effectiveness of preoperative PNI in the prognosis prediction of patients after anticancer drug therapy [26]. It can also be used as a biomarker to predict therapeutic efficacy, even in immune checkpoint inhibitor (ICI) monotherapy [27].

In general, the PNI is an immunonutritional indicator, and the neutrophil/lymphocyte ratio (NLR) reflects the inflammatory status, both of which are of high accuracy, low cost, and high reproducibility with wide application in blood surveys. Therefore, the innovation of this research is to explore their implications in the prognosis evaluation of patients who received TT for advanced HCC.

2. Materials and Methods

2.1. Research Participants. A retrospective analysis of 83 advanced HCC patients' records treated between January 2018 and June 2020 in the Second Affiliated Hospital of Anhui Medical University was conducted. The male-tofemale ratio, age (years old) range, as well as the mean age of patients were 71:12, 27-82, and 57.31 ± 11.85, respectively. Of them, 40 cases were pathologically confirmed and recurred after surgical treatment and relapsed again after TACE, and 43 cases of primary HCC were diagnosed by biopsy. Inclusion criteria: (1) diagnosis of HCC by cytology; (2) Barcelona clinic Liver Cancer (BCLC) stage [28]: B/C; (3) those unsuitable for conventional therapy or relapsed after conventional treatment and were therefore given molecular targeted drug therapy; (4) available blood routine and biochemical examination data within one week before TT; and (5) complete clinical data and follow-up. Exclusion criteria: (1) blood system or immune system diseases; (2) presence of a secondary tumor; (3) recent blood transfusions; (4) serious cardiac, pulmonary, hepatic, or renal dysfunction; and (5) Child-Pugh class C [29]. This study has obtained approval from the hospital's Ethical Committee.

2.2. Data Collection and Treatment Methods. Clinicopathological data of patients were collected, including sex, age, alcoholism history, BCLC stage, Eastern Cooperative Oncology Group (ECOG) score, Child–Pugh classification, as well as blood routines and biochemical and tumor marker indexes one week before treatment. Preoperative PNI = serum ALB (g/L) + 5 × PB LY count ($10^9/L$) [30]. NLR = neutrophil (NEU) count ($\times 10^9/L$)/LY count ($\times 10^9/L$).

Treatment: all patients received oral sorafenib (400 mg/ time, twice a day) [31], with every 28 days as a cycle, which was withdrawn when tumor progression or intolerable adverse reactions were observed. Other antitumor treatments were discontinued during the medication.

2.3. Efficacy Evaluation and Follow-Up. Efficacy evaluation [32] (complete response, CR; partial response, PR; stable disease, SD; and progressive disease, PD) was performed after \geq 2 cycles of treatment by referring to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Disease control rate (DCR) = (CR + PR + SD) cases/total number of cases × 100%.

The follow-up was as of December 2021. The follow-up data were obtained through telephone or last hospitalization records and outpatient review results, and the OS (time from initiation of TT to the last follow-up or patient death derived from any cause) was calculated.

2.4. Statistical Processing. The software used for data statistical analysis was the SPSS 23.0 (IBM, New York, NY, USA). The X-tile (version 3.6.1) was used for the diagnostic thresholds of the NLR and PNI [33]. The intergroup comparison of the quantitative data (denoted as Mean ± SD) employed the *t*-test. Enumeration data was described as *n* (%), and the difference between the groups was tested by the χ^2 or Fisher exact probability test. For the patient survival, the visualization, comparison as well as univariate and multivariate analyses were carried out by the Kaplan–Meier curves, the log-rank test, and the Cox proportional hazard regression models, respectively. Sensitivity, specificity, and area under the curve (AUC) were calculated by the receiver operator characteristic (ROC) curves. *P* < 0.05 was the significance level ($\alpha = 0.05$).

3. Results

3.1. Determination of Optimal Critical Values of the PNI and NLR. The optimal cutoffs of the NLR and PLR were defined as those with the minimum *P* value of the log-rank test in the X-tile (Figure 1). Therefore, 42.9 and 2.4 were used as the optimal thresholds for the PNI and NLR, respectively, based on which, the participants were assigned to the low-PNI (\leq 42.9) and high-PNI (>42.9) as well as the low-NLR (\leq 2.4) and high-NLR (>2.4) groups.

3.2. Association of the Different PNI and NLR Levels with Patients' Clinicopathological Features. According to the optimal thresholds of the PNI and NLR, cases were assigned to low-PNI (n = 10) and high-PNI (n = 73) as well as low-NLR (n = 64) and high-NLR (n = 19) groups. The relationship between the PNI, NLR, and related clinicopathological features was further analyzed. As indicated in Table 1, the pretreatment level of the PNI was significantly correlated with patients' alcoholism history (P < 0.05) but had no obvious correlation with patients' other clinicopathological features (P > 0.05). While no notable association was present between the pretreatment NLR level with all clinicopathological features (P > 0.05; Table 2).

3.3. Correlation of the PNI and NLR with Short-Term Efficacy. A significant inverse relationship between the PNI and NLR was identified by the Spearman correlation analysis (Figure 2). Short-term efficacy evaluation was completed in all patients, and we determined 24 cases of CR, 27 of PR, 9 of SD, and 23 of PD, with a DCR of 72.3%. No statistical difference was determined in the DCR between the high-PNI group and the low-PNI group and the low-NLR group and the low-NLR group (57.9% vs 76.6%; $\chi^2 = 3.2131$, P = 0.0731), as indicated by Table 3.

3.4. Survival of the Different PNI and NLR Groups. The survival status in different subgroups was analyzed using the Kaplan–Meier method, so as to determine the predictive capacity of the two for patients' OS after TT. The results showed a worse postoperative survival rate in the PNI \leq 42.9 group compared with the PNI >42.9 group (P < 0.05;

Figure 3(a)) and a better postoperative survival rate of patients in the NLR ≤ 2.4 group versus the NLR > 2.4 group (P < 0.05; Figure 3(b)).

3.5. Predictive Utility of the PNI and NLR for Patient Prognosis. The ROC analysis yielded an AUC of 0.7265 and 0.8083 based on the PNI and NLR, respectively (Figure 4), suggesting their reliability in predicting patients' OS.

3.6. Analysis of Related Factors Affecting Patients' OS. In the univariate regression analysis, the factors that had an obvious correlation with OS were determined to be PNI (P < 0.05, HR = 0.209, 95% CI: 0.114–0.382) and NLR (P < 0.05, HR = 2.566, 95% CI: 1.498–4.397), as shown in Table 4. Then, the two variables were included in the multivariate regression analysis, and no collinearity between PNI and NLR was confirmed by linear regression analysis. The results of multivariate regression analysis revealed the role of both PNI and NLR as independent influencing factors for patients' OS (Table 5).

4. Discussion

In this study, the PNI and NLR of 83 patients receiving TT for advanced HCC were analyzed. The cut-off point was determined by X-tile, based on which the participants were assigned to high or low PNI/NLR groups. The results identified an obvious association between PNI and alcoholism history of advanced HCC patients. The PNI, calculated from the serum ALB content and the total count of PB LYs, was initially developed for the assessment of perioperative nutritional status and surgical risk of patients with gastrointestinal surgery. The PNI combines two indexes, namely, the serum concentration of ALB and the total count of PB LYs. As a vital metabolic organ, the liver is responsible for the synthesis of ALB and the long-term insufficient protein intake can cause a decrease in the ALB. Hence, ALB, an indicator of chronic protein malnutrition, can be used to assist in assessing the general nutritional condition of patients. The occurrence of liver tumors will aggravate malnutrition and may further weaken the antitumor and antitumor metastasis reaction [34, 35]. The total LY count can also reflect the patients' nutritional status and immune function. Malnutrition and low cellular immune function can decrease the total number of LYs [36]. The NLR is a systemic inflammation marker, and the early initiation of inflammation is a proinflammatory action mediated by macrophages, NEUs, and monocytes through releasing inflammatory factors [37]. In addition, a strong correlation between the PNI level and alcoholism history was identified, which was similar to the research of Chan et al. [38] who found that the preoperative PNI level was strongly correlated with the history of alcoholism in patients after LC surgery, while the NLR was significantly related to surgical treatment (with or without). As we all know, invasive surgery will affect the body's inflammatory state, resulting in postoperative complications, infections, etc. Zahorec et al. [39] showed that the gradual rise of LYs and the gradual decline of NEUs



FIGURE 1: Determination of optimal critical values of the prognostic nutritional index (PNI) and neutrophil/lymphocyte ratio (NLR) by the X-tile. (a) The optimal threshold for the NLR and (b) the optimal threshold for the PNI.

Indicators	Low-PNI group $(n = 10)$	High-PNI group $(n = 73)$	χ^2/t	Р
Gender			2.2221	0.1362
Male	7 (70.0)	64 (87.7)		
Female	3 (30.0)	9 (12.3)		
Age			0.6349	0.4256
	4 (40.0)	39 (53.4)		
>56	6 (60.0)	34(46.6)		
History of alcoholism			9.1451	0.0025
Yes	10 (100.0)	36 (49.3)		
No	0 (0)	37 (50.7)		
ECOG score			0.4017	0.5262
0-1	6 (60.0)	36 (49.3)		
2	4 (40.0)	37 (50.7)		
Child-Pugh classification			1.7111	0.1908
A	7 (70.0)	35 (47.9)		
В	3 (30.0)	38 (52.1)		
BCLC stage			0.2229	0.6368
В	4 (40.0)	35 (47.9)		
С	6 (60.0)	38 (52.1)		
Maximum tumor diameter			0.4017	0.5262
≤5 cm	4 (40.0)	37 (50.7)		
>5 cm	6 (60.0)	36 (49.3)		
Number of lesions			0.2625	0.6084
Single	3 (30.0)	28 (38.4)		
Multiple	7 (70.0)	45 (61.6)		
Surgery			0.6349	0.4256
Yes	6 (60.0)	34 (46.6)		
No	4 (40.0)	39 (53.4)		

TABLE 1: Comparison of patients' clinicopathological features between the different PNI groups.

Note. PNI, prognostic nutritional index; NLR, neutrophil/lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona clinic liver cancer. Bold text: statistically significant.

occurred simultaneously with the improvement of the clinical status of some major stress and systemic inflammatory responses. However, in our study, surgical treatment, with or without, was found to influence the NLR level.

The study also found a higher survival rate in the high-PNI group versus the low-PNI group and a lower survival rate in the high-NLR group versus the low-NLR group. Univariate and multivariate analyses identified the independence of the PNI and NLR as prognostic indicators for advanced HCC patients who received TT. The PNI and NLR have been indicated as independent prognostic indicators for HCC patients undergoing surgery [40, 41], as well as independent risk factors for early postoperative recurrence. Also, Gulmez A found that lower PNI (<38.25) values indicated lower PFS and rates in HCC [42]. The reason why the

Journal of Oncology

	1 1 1 0)	0 1	
Indicators	Low-NLR group $(n=64)$	High-NLR group $(n = 19)$	χ^2/t	Р
Gender			0.0353	0.8509
Male	55 (85.9)	16 (84.2)		
Female	9 (14.1)	3 (15.8)		
Age			1.8671	0.1719
≤56	29 (45.3)	12 (63.2)		
>56	35 (54.7)	7 (36.8)		
History of alcoholism			0.5969	0.4398
Yes	34 (53.1)	12 (63.2)		
No	30 (46.9)	7 (36.8)		
ECOG score			0.1031	0.7481
0-1	33 (51.6)	9 (47.4)		
≥2	31 (48.4)	10 (52.6)		
Child-Pugh classification			0.1031	0.7481
A	33 (51.6)	9 (47.4)		
В	31 (48.4)	10 (52.6)		
BCLC stage			0.0014	0.9698
В	30 (46.9)	9 (47.4)		
С	34 (53.1)	10 (52.6)		
Maximum tumor diameter			0.9290	0.3351
≤5 cm	35 (54.7)	8 (42.1)		
>5 cm	29 (45.3)	11 (57.9)		
Number of lesions			0.2382	0.6255
Single	23 (35.9)	8 (42.1)		
Multiple	41 (64.1)	11 (57.9)		
Surgery			2.2101	0.1371
Yes	28 (43.8)	12 (63.2)		
No	36 (56.2)	7 (36.8)		

TABLE 2: Comparison of patients' clinicopathological features between the different NLR groups.

Note. PNI, prognostic nutritional index; NLR, neutrophil/lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona clinic liver cancer. Bold text: statistically significant.



FIGURE 2: Correlation between the prognostic nutritional index (PNI) and neutrophil/lymphocyte ratio (NLR).

PNI can be used as a prognostic indicator for HCC patients may be because LYs are mainly involved in immune response, with the capacity of inhibiting tumor cell multiplication and metastasis [24]. The decrease in LY count, in contrast, weakens the systemic immune system, which allows the cancer cells to escape immunological surveillance easily, ultimately leading to an enhanced malignant phenotype of cancer cells. The serum ALB is the simplest and most efficient index that can reflect the body's nutritional condition and is the decisive factor in the immune response of cancer cells [43]. Hypoalbuminemia reduces the general immune system, resulting in tumour cell proliferation. Hence, the combination of LYs and serum ALB can better predict the outcomes of cancer patients. Furthermore, the NLR is one of the indicators reflecting immune status, which can be used to assess the body's antitumor inflammatory status. And, the NEUs can promote vascular endothelial growth factor secretion, inducing angiogenesis and tumour progression, thus predicting adverse clinical outcomes. Lymphocytosis is related to the immune escape of tumor cells, and the NEUs can inhibit the lethality of LYs [44]. Taken together, there are good reasons why the PNI and NLR can be used as independent predictors.

The present research has several limitations that need to be addressed. First, this is a retrospective, single-center study with limited cases included, requiring a large sample size to further validate the conclusions. Second, dividing the patients into two groups using data-derived cut-off values might lead to a decrease in statistical power and incomplete correction for confounding factors [45, 46]. Third, there are many factors that affect patient outcomes in addition to nutritional status and immune microenvironment, while many other biomarkers were not investigated because relevant data on the side effects of targeted therapies are lacking. Hence, a multicentric, large sample size, welldesigned prospective study is needed to identify the

<u></u>	DCR			DD
Groups	CR	PR	SD	PD
Low-PNI group $(n = 10)$	2 (20.0)	3 (30.0)	2 (20.0)	3 (30.0)
High-PNI group $(n = 73)$	22 (30.1)	24 (32.9)	7 (9.6)	20 (27.4)
χ^2/t	0.0122			
P	0.9121			
Low-NLR group $(n = 64)$	23 (35.9)	20 (31.3)	6 (9.4)	15 (23.4)
High-NLR group $(n = 19)$	1 (5.3)	7 (36.8)	3 (15.8)	8 (42.1)
χ^2	3.2131			
Р	0.0731			

TABLE 3: The short-term efficacy of patients in different PNI and NLR groups.

Note. PNI, prognostic nutritional index; NLR, neutrophil/lymphocyte ratio.



FIGURE 3: Survival analysis of the different prognostic nutritional index (PNI) and neutrophil/lymphocyte ratio (NLR) groups. (a) The Kaplan–Meier curve of the patients' overall survival rate in high- and low-PNI groups. (b) The Kaplan–Meier curve of the patients' overall survival rate in high- and low-PNI groups.



FIGURE 4: The receiver operating characteristic (ROC) analysis of sensitivity and specificity. (a) The ROC curves for the prognostic nutritional index PNI, and (b) ROC curves for the neutrophil/lymphocyte ratio NLR. *Note.* AUC: area under the curve.

Journal of Oncology

Prognostic factors	β	Se	Hazard ratio (95% CI)	Р
Sex	0.234	0.356	1.263 (0.628-2.540)	0.512
Age	0.018	0.011	1.018 (0.996-1.040)	0.108
PNI	-1.565	0.308	0.209 (0.114-0.382)	< 0.001
NLR	0.942	0.275	2.566 (1.498-4.397)	0.001
History of alcoholism	0.404	0.248	1.498 (0.921-2.437)	0.103
ECOG score	0.147	0.250	1.159 (0.710-1.890)	0.555
Child–Pugh classification	-0.142	0.247	0.867 (0.535-1.407)	0.564
BCLC stage	-0.226	0.250	0.798 (0.489-1.303)	0.367
Maximum tumor diameter	0.220	0.251	1.246 (0.762-2.037)	0.380
Number of lesions	0.263	0.259	1.301 (0.782-2.163)	0.311

TABLE 4: Univariate regression analysis.

Note. PNI, prognostic nutritional index; NLR, neutrophil/lymphocyte ratio; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona clinic Liver Cancer. Bold text: statistically significant.

TABLE 5: Multivariate regression analysis.

	β	SE	ratio (95% CI)	Р
Ĺ	-1.415	0.306	0.243 (0.133-0.443)	< 0.001
2	0.811	0.279	2.251 (1.304-3.885)	0.004
R	-1.415 0.811	0.306 0.279	0.243 (0.133–0.443) 2.251 (1.304–3.885)	

Note. PNI, Prognostic Nutritional Index; NLR, neutrophil/lymphocyte ratio. Bold text: statistically significant.

efficacy and accuracy of the PNI and NLR for prognosis prediction of HCC patients receiving TT.

5. Conclusion

In conclusion, pretreatment PNI and NLR levels have great prognostic implications for advanced HCC patients undergoing TT. High NLR and Low PNI values suggest that this patient may have malnutrition and poor immune function, which is associated with an adverse prognosis. However, sorafenib monotherapy also shows great survival benefits in some patients. What matters is to identify biomarkers to predict which treatment a target patient will benefit most from. Using the markers in our study, it is possible to identify the patient population that is suitable for TT. We believe that such biomarkers can be used to identify suitable patients, especially in countries where not every patient has access to appropriate treatment for financial reasons. These tests have the advantage of being inexpensive, easy to calculate, and standardize.

Data Availability

The labeled dataset used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by the National Natural Science Foundation Incubation Program of the Second Affiliated Hospital of Anhui Medical University (no.: 2019GQFY13) and the Fund support by Anhui Medical University (no.: 2020xkj035) to XN Pang.

References

- J. C. Mejia and J. Pasko, "Primary liver cancers: intrahepatic cholangiocarcinoma and hepatocellular carcinoma," *Surgical Clinics of North America*, vol. 100, no. 3, pp. 535–549, 2020.
- [2] H. Sung, J. Ferlay, R. L. Siegel et al., "Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: A Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021.
- [3] H. Matsushita and A. Takaki, "Alcohol and hepatocellular carcinoma," *BMJ open gastroenterology*, vol. 6, no. 1, Article ID e000260, 2019.
- [4] J. Llovet, M. Ducreux, R. Lencioni, A. Di Bisceglie, P. Galle, and J. Dufour, "European association for the study of the liver european organisation for research and treatment of cancer: easl-eortc clinical practice guidelines: management of hepatocellular carcinoma," *Journal of Hepatology*, vol. 56, pp. 908–943, 2012.
- [5] T. Hatanaka, H. Arai, and S. Kakizaki, "Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma," *World Journal of Hepatology*, vol. 10, no. 7, pp. 485–495, 2018.
- [6] Y. Xie, H. Tian, and H. Xiang, "Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?" *Tumori Journal*, vol. 107, no. 4, pp. 292–303, 2020.
- [7] S. Xia, Y. Pan, Y. Liang, J. Xu, and X. Cai, "The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma," *EBioMedicine*, vol. 51, Article ID 102610, 2020.

- [8] M. Kudo, R. S. Finn, S. Qin et al., "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial," *The Lancet*, vol. 391, no. 10126, pp. 1163–1173, 2018.
- [9] R. K. Kelley, P. Mollon, J.-F. Blanc et al., "Comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma," *Advances in Therapy*, vol. 37, no. 6, pp. 2678–2695, 2020.
- [10] R. S. Finn, S. Qin, M. Ikeda et al., "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma," *New England Journal of Medicine*, vol. 382, no. 20, pp. 1894–1905, 2020.
- [11] A. X. Zhu, Y.-K. Kang, C.-J. Yen et al., "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (reach-2): a randomised, double-blind, placebo-controlled, phase 3 trial," *The Lancet Oncology*, vol. 20, no. 2, pp. 282–296, 2019.
- [12] F. Piñero, M. Dirchwolf, and M. G. Pessôa, "Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment," *Cells*, vol. 9, no. 6, 2020.
- [13] T. Namikawa, K. Yokota, S. Yamaguchi et al., "Evaluation of systemic inflammatory response and nutritional biomarkers as predictive factors in patients with recurrent gastric cancer," *Oncology*, vol. 98, no. 7, pp. 452–459, 2020.
- [14] S. M. Crusz and F. R. Balkwill, "Inflammation and cancer: advances and new agents," *Nature Reviews Clinical Oncology*, vol. 12, no. 10, pp. 584–596, 2015.
- [15] L. Zitvogel, F. Pietrocola, and G. Kroemer, "Nutrition, inflammation and cancer," *Nature Immunology*, vol. 18, no. 8, pp. 843–850, 2017.
- [16] H. Mandaliya, M. Jones, C. Oldmeadow, and I. I. C. Nordman, "Prognostic biomarkers in stage iv non-small cell lung cancer (nsclc): neutrophil to lymphocyte ratio (nlr), lymphocyte to monocyte ratio (lmr), platelet to lymphocyte ratio (plr) and advanced lung cancer inflammation index (ali)," *Translational Lung Cancer Research*, vol. 8, no. 6, pp. 886–894, 2019.
- [17] J.-X. Lin, Z.-K. Wang, Y.-Q. Huang et al., "Dynamic changes in pre-and postoperative levels of inflammatory markers and their effects on the prognosis of patients with gastric cancer," *Journal of Gastrointestinal Surgery*, vol. 25, no. 2, pp. 387–396, 2021.
- [18] S. Itoh, K. Yugawa, M. Shimokawa et al., "Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection," *BJS Open*, vol. 3, 2019.
- [19] J. V. Barreira, "The role of nutrition in cancer patients," *Nutrition and Cancer*, vol. 73, pp. 2849-2850, 2021.
- [20] T. Kubota, K. Shoda, H. Konishi, K. Okamoto, and E. Otsuji, "Nutrition update in gastric cancer surgery," *Annals of gas*troenterological surgery, vol. 4, pp. 360–368, 2020.
- [21] B. F. Smale, J. L. Mullen, G. P. Buzby, and E. F. Rosato, "The efficacy of nutritional assessment and support in cancer surgery," *Cancer*, vol. 47, no. 10, pp. 2375–2381, 1981.
- [22] X. Zhang, W. Zhao, X. Chen et al., "Combining the fibrinogen-to-pre-albumin ratio and prognostic nutritional index (fpr-pni) predicts the survival in elderly gastric cancer patients after gastrectomy," *OncoTargets and Therapy*, vol. 13, pp. 8845–8859, 2020.
- [23] S. Li, G. Tian, Z. Chen, Y. Zhuang, and G. Li, "Prognostic role of the prognostic nutritional index in pancreatic cancer: a meta-analysis," *Nutrition and Cancer*, vol. 71, no. 2, pp. 207–213, 2019.
- [24] K. Okadome, Y. Baba, T. Yagi et al., "Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in

patients with esophageal cancer," Annals of Surgery, vol. 271, no. 4, pp. 693–700, 2020.

- [25] K. Sun, S. Chen, J. Xu, G. Li, and Y. He, "The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis," *Journal of Cancer Research and Clinical Oncology*, vol. 140, no. 9, pp. 1537–1549, 2014.
- [26] Y. Hu, J. Shen, R. Liu et al., "Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: a systematic review and meta-analysis," *The International Journal of Biological Markers*, vol. 33, no. 4, pp. 372–378, 2018.
- [27] F. Shoji, H. Takeoka, Y. Kozuma et al., "Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors," *Lung Cancer*, vol. 136, pp. 45–51, 2019.
- [28] R. Golfieri, I. Bargellini, C. Spreafico, and F. Trevisani, "Patients with barcelona clinic liver cancer stages b and c hepatocellular carcinoma: time for a subclassification," *Liver cancer*, vol. 8, no. 2, pp. 78–91, 2019.
- [29] F. Durand and D. Valla, "Assessment of the prognosis of cirrhosis: Child-pugh versus meld," *Journal of Hepatology*, vol. 42, no. 1, pp. S100–S107, 2005.
- [30] D. Wang, X. Hu, L. Xiao et al., "Prognostic nutritional index and systemic immune-inflammation index predict the prognosis of patients with HCC," *Journal of Gastrointestinal Surgery*, vol. 25, no. 2, pp. 421–427, 2021.
- [31] Y. Futsukaichi, K. Tajiri, S. Kobayashi et al., "Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature," *Clinical Journal of Gastroenterology*, vol. 12, no. 2, pp. 128–134, 2019.
- [32] S. G. Armato and A. K. Nowak, "Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1)," *Journal of Thoracic Oncology*, vol. 13, no. 7, pp. 1012–1021, 2018.
- [33] R. L. Camp, M. Dolled-Filhart, and D. L. Rimm, "X-Tile: a new bio-informatics tool for biomarker assessment and outcomebased cut-point optimization," *Clinical Cancer Research*, vol. 10, no. 21, pp. 7252–7259, 2004.
- [34] B. Li, Z. Lu, S. Wang et al., "Pretreatment elevated prognostic nutritional index predicts a favorable prognosis in patients with prostate cancer," *BMC Cancer*, vol. 20, pp. 361–367, 2020.
- [35] M. Ke, T. Xu, N. Li et al., "Prognostic nutritional index predicts short-term outcomes after liver resection for hepatocellular carcinoma within the milan criteria," *Oncotarget*, vol. 7, no. 49, pp. 81611–81620, 2016.
- [36] A. F. Bullock, S. L. Greenley, G. A. G. McKenzie, L. W. Paton, and M. J. Johnson, "Relationship between markers of malnutrition and clinical outcomes in older adults with cancer: systematic review, narrative synthesis and meta-analysis," *European Journal of Clinical Nutrition*, vol. 74, no. 11, pp. 1519–1535, 2020.
- [37] I. T. Schobert, L. J. Savic, J. Chapiro et al., "Neutrophil-tolymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after deb-tace," *European Radiology*, vol. 30, no. 10, pp. 5663–5673, 2020.
- [38] A. W. H. Chan, S. L. Chan, G. L. H. Wong et al., "Prognostic nutritional index (pni) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection," *Annals of Surgical Oncology*, vol. 22, no. 13, pp. 4138–4148, 2015.
- [39] R. Zahorec, "Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill," *Bratislavske Lekarske Listy*, vol. 102, pp. 5–14, 2001.

- [40] V. G. Shelat, "Role of inflammatory indices in management of hepatocellular carcinoma—neutrophil to lymphocyte ratio," *Annals of Translational Medicine*, vol. 8, no. 15, 2020.
- [41] C. Liu, L. Li, W.-S. Lu et al., "Neutrophil-lymphocyte ratio plus prognostic nutritional index predicts the outcomes of patients with unresectable hepatocellular carcinoma after transarterial chemoembolization," *Scientific Reports*, vol. 7, pp. 13873–13878, 2017.
- [42] A. Gulmez and H. Harputluoglu, "Advanced hepatocellular cancer treated with sorafenib and novel inflammatory markers," *Journal of Gastrointestinal Cancer*, pp. 1–9, 2022.
- [43] D. Kuroda, H. Sawayama, J. Kurashige et al., "Controlling nutritional status (conut) score is a prognostic marker for gastric cancer patients after curative resection," *Gastric Cancer*, vol. 21, no. 2, pp. 204–212, 2018.
- [44] L. Wong, K. Bozhilov, B. Hernandez et al., "Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio," *Clinical and Molecular Hepatology*, vol. 25, no. 3, pp. 305–316, 2019.
- [45] D. G. Altman and P. Royston, "The cost of dichotomising continuous variables," *BMJ*, vol. 332, no. 7549, Article ID 10801, 2006.
- [46] P. Royston, D. G. Altman, and W. Sauerbrei, "Dichotomizing continuous predictors in multiple regression: a bad idea," *Statistics in Medicine*, vol. 25, no. 1, pp. 127–141, 2006.